BIOMAT Database Logo BIOMAT Database Logo

Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. 1994

A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Kaplan Cancer Center, Division of Medical Oncology, New York University Medical Center, New York 10016.

Twenty-four patients with solid malignancies were treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) on a Phase 1b trial. The objective of the study was to evaluate the effects of GM-CSF on peripheral blood monocyte activation. GM-CSF was administered by subcutaneous injection daily for 14 days. Immune parameters measured were monocyte cytotoxicity against the human colon carcinoma (HT29) cell line, serum tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and in vitro TNF-alpha and IL-1 beta induction. All patients were evaluable for toxicity. Fifteen patients were evaluable for immunologic response. Treatment with GM-CSF led to a statistically significant enhancement in direct monocyte cytotoxicity against HT29 cells. There was no increase in serum TNF-alpha or IL-1 beta and no consistent in vitro induction of TNF-alpha or IL-1 beta from monocytes posttreatment. Treatment was well tolerated overall. We conclude that treatment with GM-CSF can lead to enhanced monocyte cytotoxicity. Further studies are in progress to evaluate the effect of GM-CSF on other parameters of monocyte functions.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte colony-stimulating factor administration and monocyte phenotype.
June 1996, Experimental hematology,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1).
July 1992, The New England journal of medicine,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2).
July 1992, The New England journal of medicine,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy.
September 1997, British journal of haematology,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte-macrophage colony-stimulating factor.
January 1990, Immunology series,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte-macrophage colony-stimulating factor.
January 1990, Biotherapy (Dordrecht, Netherlands),
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
[Granulocyte-macrophage colony-stimulating factor].
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
[Granulocyte-macrophage colony-stimulating factor].
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Granulocyte-macrophage colony-stimulating factor.
July 1991, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,
A Chachoua, and R Oratz, and R Hoogmoed, and D Caron, and D Peace, and L Liebes, and R H Blum, and J Vilcek
Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration.
May 1988, Cancer research,
Copied contents to your clipboard!